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During the last 20 years, at times in association with over-
enthusiastic publicity in the non-medical media (Toufexis &
Juscius, 1980), there have been two false dawns of excite-
ment about a biological cure for cancer (i.e., tumour vac-
cines, Mathe et al., 1969; and interferon, Strander et al.,
1974). Following a period of disillusionment when the initial
high promise was not realised (Powles et al., 1977) both
ultimately have had a lasting impact in a small area of
treatment, i.e., intravesical BCG in superficial bladder cancer
(Pinsky et al., 1985) and interferon in hairy cell leukaemia
(Kirkwood & Ernstoff, 1984). In retrospect this is perhaps
hardly surprising. Despite impressive data from animal
models (Mathe et al., 1969; Gresser & Bourali, 1970) and
laboratory studies (Mathe et al., 1969; Gresser et al., 1970;
Oliver, 1982; Krown, 1986) the BCG+ allogeneic tumour cell
vaccination (Mathe et al., 1969) and interferon clinical
studies (Strander et al., 1974) which provoked the initial
interest were adjuvant trials. These trials were undertaken
before the efficacy of the treatment had been tested in
patients with measurable disease and reported results from
treating less than 20 disease-free patients after conventional
treatment and compared their disease-free survival to histori-
cal controls.
Recently a third phase of excitement and excessive opti-
mistic publicity (Bylinsky, 1985; Anon., Wall Street Journal,
1985) over a potential new biological treatment of cancer has
been generated from the first results of the use of interleukin
2 (IL-2) in phase I/II clinical trials (Rosenberg et al., 1985).
Although IL-2 needs more extensive clinical and laboratory
evaluation, there is, however, a material difference in the
quality and quantity of early phase I/II data which is fuelling
interest in this lymphokine. There have been reports of
complete remission of advanced metastatic disease in both
chemotherapy resistant and sensitive tumours such as renal
cell (Rosenberg et al., 1987), melanoma (Rosenberg et al.,
1987), bladder (Pizza et al., 1984), and head and neck cancer
(Taguchi & Kimoto, 1986) as well as lymphoma (Rosenberg
et al., 1987; West et al., 1987). In fact, the data from the first
phase I/II study of evaluation of IL-2 plus lymphokine
activated killer (LAK) cells are nearly as impressive as those
from the original phase I testing of cisplatin (Table I,
Rosenberg et al., 1987; Higby et al., 1974) prior to its
successful incorporation into curative combination treatment
for testis cancer (Einhorn & Donoghue, 1977; Oliver, 1986).
This review will briefly discuss the role of IL-2 in the
physiology of the immune response prior to a detailed
examination of the results from the initial phase I/II trials
and an assessment of the future potential of this lymphokine
on the basis of the latest preclinical laboratory studies.
Physiology of IL-2
Interleukin-2 (IL-2), originally known as T cell growth
factor, was discovered in the supernatants of PHA stimu-
lated lymphocyte cultures (Morgan et al., 1976). It was
shown to act as a T cell growth factor (for review see
Larrson, 1986; and Taniguchi et al., 1986) enabling cloning
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of T cells (Smith, 1980). In addition, it was found to be
produced constitutively by some T cell leukaemias (Gillis &
Watson, 1980) which provided a source for clinical and
laboratory studies until recombinant IL-2 was first produced
five years ago by Taniguchi et al. (1983). Now there are at
least six different recombinant IL-2 preparations (Thurman
et al., 1986), four of which are currently undergoing clinical
trials.
The property of IL-2 responsible for the interest in its
application as a cancer treatment is its ability to induce
marked expansion of T lymphocytes in vitro. The reason that
this property has excited interest is that in certain animal
tumours T lymphocytes play an important role in tumour
and allograft rejection and it has long been known that they
are more efficient than serum in transferring immunological
memory for transplantation and tumour resistance (Mitchi-
son, 1953; Woodruff et al., 1963). This is presumed to be
mediated by cytolytic T lymphocytes (CTL), as these cells,
whether generated by in vivo or in vitro immunisation can
produce regression of established tumour on transfer to
syngeneic tumour bearing hosts (Woodruff et al., 1963;
Delorme & Alexander, 1964; Rosenberg & Terry, 1977) more
effectively than immune serum (Rosenberg & Terry, 1977).
In man there is less evidence for specific antitumour CTL,
though there have been three reports over the last 10 years
demonstrating their existence, albeit in less than 50% of
patients with a variety of different tumours (Lee & Oliver,
1978; Oliver & Lee, 1979a,b; Vose et al., 1978; Vanky et al.,
1987). However, it was the discovery that IL-2 produced in
vitro activation of the peripheral blood and tumour infiltrat-
ing mononuclear cells of virtually all patients with malignant
tumours which first raised interest in its clinical potential.
This effect was not immunologically specific as it led to the
development of broadly cross reacting non-MHC restricted
antitumour cytotoxic cells, though they did express some T
cell antigens. Those that grew out from peripheral blood
cells were designated as lymphokine activated killer (LAK)
cells (Grimm et al., 1982) while those grown from tumour
cell suspensions were designated tumour infiltrating lympho-
cytes (TIL - see below). Though LAK cells showed no
killing of normal autologous lymphocytes (Grimm et al.,
1982) they did not show specificity for the patient's tumour
and cross reacted extensively with other tumours (Rayner et
al., 1985). In some situations LAK cells have been shown to
react with autologous con A activated normal T cells (Muul
et al., 1986) suggesting that the target antigen recognized is
not truly tumour specific but is also present on some, but
not all, actively replicating cells. There is some evidence that
PHA activated blasts may be less susceptible to this cross
reactivity (Slovin et al., 1986).
The precise relationship of the IL-2 activated killer cells to
the cells present in peripheral blood prior to treatment with
IL-2 known as natural killer cells (NK), is uncertain. The
distinction is perhaps artificial as there is now increasing
acceptance that LAK and NK cells are derived from a
common progenitor cell, and IL-2 simply acts to amplify and
broaden the cytotoxic mechanism (Ortaldo & Herberman,
1984; Grossman & Herberman, 1986; Schmidt et al., 1986).
The more critical issue is to clarify the relationship between
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the non-MHC restricted cytotoxic cells expressing some T
cell characteristics and expressing LAK activity and the
better characterised MHC restricted cytotoxic T cells. This is
particularly so now that it has been possible to induce
cytotoxic T cells in nude mice using IL-2 (Wagner et al.,
1980) and demonstrate reversion of clones of antigen specific
CTL to broadly reactive LAK like cells (Havele et al., 1986),
given the observation that NK cells and CTL may share a
similar cytolytic mechanism (Yannelli et al., 1986; Liu et al.,
1986).
Initial animal and clinical studies of IL-2 and IL-2 activated
cytotoxic cells
It was Rosenberg whose animal studies first demonstrated
the therapeutic potential of LAK cells combined with IL-2
(Yron et al., 1980; Rosenstein et al., 1984; Mule et al., 1984;
Lafreniere & Rosenberg, 1985; Mazumder & Rosenberg,
1984; Mazumder et al., 1984; Lotze et al., 1985). Though
LAK cells alone had no therapeutic effect and extremely
high doses of IL-2 alone only a weak effect, together they
were synergistic in eliminating established metastases and in
prolonging survival of animals with tumours of variable
degrees of immunogenicity (Rosenstein et al., 1984; Mule et
al., 1984; Lafreniere & Rosenberg, 1985; Mazumder &
Rosenberg, 1984). As a consequence of these results, clinical
trials first of cells (Mazumder et al., 1984) alone and then
IL-2 alone (Lotze et al., 1985) and finally the combination
(Rosenberg et al., 1985, 1987) were undertaken (Table I). At
the time that these results were published because the
tumours selected for study were chemoresistant they
attracted an even greater publicity outside the medical
literature (Bylinsky, 1985; Anon., Wall Street Journal, 1985)
than did interferon in the late 1970s. This had diminished to
a certain extent since the first analysis of subsequent phase II
studies (Chase, 1986).
The response rate has fallen as more cases and further
centres have taken up the complex treatment procedure
(West et al., 1987; Fisher et al., 1987; Dutcher et al., 1987)
and reported results after limited experience (Table II),
though responses including durable (>1 yr) complete
remissions have been demonstrated in the same spectrum of
chemo-resistant tumours.
In addition to disapproval over the excessive publicity in
the non medical media, there has been considerable criticism
(Mortel, 1986) directed at the clinical approach of
Rosenberg. As is traditional in phase I studies he treated
patients with as high a dose of IL-2 as the patients could
Table I Comparison of initial phase I
IL-2/LAK.
studies of cisplatin and
No.
patients Responses
Cisplatin 45 3CR; 9PR (27%)
(Higby et al., 1974)
IL-2/LAK 106 8CR; 15PR (22%)
(Rosenberg et al., 1987)
IL-2 alone 46 1CR; 5PR (13%)
(Rosenberg et al., 1987)
Activated cells 25 0
(Mazumder et al., 1984)
CR=complete response; PR=partial response.




Pulse IL-2+LAK 64 2CR; 9PR (17%)
Biotherapeutics
Infusion IL-2+LAK 40 OCR; 13PR (33%)
CR=complete response; PR=partial response.
tolerate. Mortel felt that the toxicity outweighed the low
therapeutic gain apparent at present. However, had this
therapeutic nihilism existed in the 1960s it is doubtful
whether clinicians would have ever undertaken the studies
which led to the present outpatient treatment for childhood
leukaemia and malignant teratoma.
The Rosenberg approach did produce severe toxicity
(Rosenberg et al., 1985, 1987), all patients needing intensive
care and occasionally ventilation. Though there were treat-
ment related deaths initially, in contrast to chemotherapy the
majority began to recover within 2-3 h of stopping IL-2 and
most were fit enough to return home 24-48 h after stopping
treatment without long term sequelae.
Toxicity of high dose IL-2+LAK cells
The list of side effects seen in these patients is very extensive
(Table III), though it is not clear how much is a direct effect
of IL-2 and how much an effect of other biological factors
such as gamma interferon known to be induced by IL-2
(Lotze et al., 1985).
The principal toxicity is fluid retention and capillary
leakage (Lotze et al., 1987; Rosenstein et al., 1986) which
manifest as weight gain and oedema, hypotension, oliguria
or anuria and in some patients hepatic pulmonary failure
and even coma if treatment is continued at high dosage
(Margolin et al., 1987). An interesting aspect of the toxicity
associated with the use of high dose IL-2 was erythrodermia
with severe pruritis occassionally producing a clinical picture
similar to that of the Mazzotti syndrome seen in patients
with micro filarial skin disease on treatment with diethyl
carbimazine (Wilcockes & Manson-Bahr, 1972).
This observation, which could be due to an autoallergic
reaction against skin or a skin commensal organism, taken
together with the anecdotal reports of autoimmune arthral-
gias and thyroiditis in patients receiving IL-2 raises the
question as to whether this lymphokine might induce auto-
immunity as well as produce an antitumour response. This is
an interesting paradox as it is now more than 25 years since
Macfarlane Burnett first speculated (Burnet, 1969; Burnet,
1976) that autoimmunity might be the extreme manifestation
of the body's mechasnism for counteracting attempts by
malignant tumours to escape from immune surveillance. As
gamma interferon is known to be induced by IL-2 (Lotze et
al., 1985) these side effects could be due to aberrant
induction of class II MHC antigen as has been speculated for
autoimmune disease occurring after viral infection
(Bottazzo et al., 1983). Despite this impressive list of tox-
icities, as they were greatly diminished in patients on steroids
(Vetto et al., 1987), steroids provide a safety net if severe
toxicity occurs, though as they also eliminate the therapeutic
effect of IL-2 they could not be used prophylactically. This
and the observation that all of this toxicity disappeared more
rapidly than those after chemotherapy, once the drug was
stopped, suggests that in the long term toxicity will not be
the major factor limiting IL-2 use.
Therapeutic endeavours attempting to reduce toxicity of IL-
2+LAK cells
There have been several attempts to find less toxic ways of
giving the treatment. Few responses were seen when repeated
courses of lower non-toxic doses of IL-2 alone were given
over a period of 4 weeks or more (Taguchi & Kimoto, 1986;
Bradley et al., 1986) and there was no increase in the
number of responses when LAK cells were added to this
lowdose IL-2 regimen in the multicentre Japanese study
(Taguchi & Kimoto, 1986).
The most significant attempt to reduce toxicity was that of
West et al., (1986) who gave the drug by continuous infusion
rather than the 8 hourly bolus injection regime used by
Rosenberg's group. Studies in animal tumour models had
demonstrated that antitumour effect related more to the
duration of exposure than to the peak levels achievedCLINICAL POTENTIAL OF IL-2 407
Table III Toxicity of IL-2+LAK.
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(Cheever et al., 1985). Furthermore, since the acute toxicity
of IL-2 is reversed rapidly when treatment is stopped,
continuous infusion provided a safer way of regulating
dosage and avoiding the crash which usually terminated
treatment when it was given by the intensive 8 hourly pulse
schedule. In fact using continuous infusion only 6/40 of the
patients of West et al. (1987) could not be managed on an
ordinary ward and the problems were even less with more
regular temporary interruption of infusions.
Recently further phase I/II testing of this type of schedule
using IL-2 alone has reported response in 9 of 18 patients
treated (Paciucci et al., 1988). From this study and that of
West et al., there is increasing evidence that the most
important marker which correlates with response is level of
lymphocyte activation demonstrated in vivo, though Cohen
et al. (1987) have demonstrated that those patients whose
tumours demonstrated enhanced HLA-DR expression during
IL-2 treatment also showed a higher frequency of response.
Influence of tumour type on response to IL-2/LAK
To date most of the phase I/II testing of IL-2/LAK has been
done in patients with primarily chemotherapy resistant renal
cell carcinoma, melanoma and colon cancer (Table IV)
(Rosenberg et al., 1987; West et al., 1987; Fisher et al., 1987;
Dutcher et al., 1987).
However, despite less data there are already tantalising
anecdotes which suggest that the response rate may be even
higher in the chemosensitive tumours such as head and neck
(Taguchi & Kimoto, 1986), bladder cancer (Pizza et al.,
1984) and relapsed lymphoma (Rosenberg et al., 1987).
Future approaches to the use of IL-2
Given that at present all the standard modalities of cancer
treatment such as surgery, radiotherapy and chemo-
therapyare immunosuppressive, IL-2 in combination will un-
doubtedly be the next direction to explore. Preliminary
results from Mitchell (1987) reporting one complete response
and five partial responses in 24 patients receiving low dose
IL-2 in combination with low dose cyclophosphamide, a
drug not known to have appreciable activity in melanoma,
provide an early indication of this potential.
A further approach for enhancing the activity of IL-2
comes from animal studies showing more than additive
antitumour activity when given in combination with either
alpha interferon (Truitt et al., 1987) or tumour necrosis
factor, though accurate assessment of therapeutic ratio and
precise dosage in these models is difficult. This is particularly
so now that there is some evidence for a bell-shaped
Table IV Tumour cell type and response to IL-2+LAK.
No. No.
Patients Responses
Renal cell 74 6CR; 14PR (27%)
Melanoma 68 2CR; 15PR (25%)
Colon 39 1 CR; 2PR (8%)
CR=complete response; PR=partial response.
Controlled by antiprostaglandins
Vomiting or diarrhoea+jaundice
Euphoria, mania, psychosis, coma
Erythrodemia - pseudo Mazzoti reaction
Like ATN but more rapidly reversed
Eosinophilia
Common but responsive to steroids
Rare and steroid sensitive
rather than linear dose response curve to these treatments
(Talmadge et al., 1987).
The future potential of activated cell therapy remains
more uncertain particularly because of their cost and logisti-
cal problems. One of the most exciting laboratory develop-
ments has been the demonstration by Rosenberg's group in
experimental animal tumours that tumour infiltrating
lymphocytes (Yron et al., 1980; Rosenberg et al., 1986) (TIL)
can be grown out of tumour cell suspensions under the
influence of IL-2 and are 100-fold more active than LAK
cells in adoptive immunotherapy models (Rosenberg et al.,
1986) and can enhance the activity of radiotherapy and
chemotherapy. Since this original publication there have
been multiple studies (Whiteside et al., 1987; Von Flidener et
al., 1987; Belldegrum & Rosenberg, 1987) showing that it is
possible to get similar cells from a large proportion of
human tumours.
Although monoclonal antibodies as therapeutic agents
have been less investigated than IL-2, there have been two
recent innovations suggesting that combinations of IL-2
activated cells and monoclonal antibodies may provide a
more immunologically specific treatment in the future.
Firstly, pretreatment of peripheral blood buffy coat cells
with anti T3 antibody prior to IL-2 activation (Ochoa et al.,
1987) was shown to enhance the generation of LAK cells
and Lotz et al. (1987) have demonstrated that cytotoxicity
was further enhanced if an anti T3 antibody was crosslinked
to a tumour specific antitumour antibody. To date there
were no clinical data to support this approach though the
preliminary results of Douillard et al. (1986) reporting 1
complete and 4 'partial' responses in 20 patients with
metastatic colon cancer treated with monoclonal antibody
bound to peripheral blood buffy coat cells does suggest that
this may be a way to make LAK cell therapy more
immunologically specific.
In conclusion, compared with the small adjuvant studies
which initiated the interest in BCG plus allogeneic tumour
cell immunotherapy and interferon, the data reviewed sug-
gest that interleukin-2 has a more secure foundation as a
treatment worth further exploration.
Although to date only chemo-insensitive tumours such as
renal cell carcinoma, melanoma, colon and lung cancer have
been adequately screened, the preliminary results in chemo-
therapy resistant lymphoma, in head and neck and bladder
cancer suggests that the use of IL-2 may not be limited to
just those tumours which have been tested to date.
The expense and complexity of the IL-2/LAK cell pro-
gramme combined with its excessive toxicity make it impor-
tant to clarify the need for LAK cell therapy as continuous
infusion may be a simpler and safer way to give the IL-2,
and have greater potential clinically.
For the future, the preliminary data from combining IL-2
with chemotherapy and those from combining TIL with both
chemotherapy and radiotherapy are most encouraging given
the known immunosuppressive effect of all three principal
cancer treatment modalities. These results and those demon-
strating synergism between IL-2 and alpha interferon or
tumour necrosis factor and LAK cells coated with mono-
clonal antibodies suggest that the full potential of this
lymphokine has yet to be realised.408 R.T.D. OLIVER
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